Evidence map›Paper›PMID 31768396›Full record

ReviewVisceral medicine2019

GLP-2 Analogues as First Specific Treatment of Intestinal Failure.

Irina Blumenstein

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Visceral medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Irina BlumensteinDepartment of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Frankfurt, Frankfurt am Main, Germany.
University Hospital Frankfurt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Growth factors and other trophic hormones play an important role in the specific treatment of intestinal failure, with teduglutide being the first approved medication specifically for use in patients with intestinal failure in conjunction with specialized nutritional support. This article focusses on the mode of action, the pivotal study data, treatment response prediction as well as new substances in phase clinical trials.

Indexed as

Growth factorsIntestinal failureMode of actionNew substances in phase clinical trialsPivotal study dataSpecific treatmentTeduglutideTreatment response predictionTrophic hormones

Identifiers

PMID31768396
PMCPMC6873062
OpenAlexW2976853431

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.